SeaStar Medical (ICU) announces that Mayo Clinic is now cleared to enroll subjects in the company’s NEUTRALIZE-AKI pivotal trial, increasing the number of activated sites to 15. “We are thrilled to activate another large academic center to our study,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “Enrollment in the trial currently stands at 76 with six subjects enrolled since the first of the year. We look forward to our next major milestone of reaching our 100th subject for our interim analysis soon.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical Gains FDA Approval for Pediatric Device
- SeaStar Medical says FDA approves feasibility study with SCD-ADULT
- SeaStar Medical begins shipping to QUELIMMUNE
- SeaStar Medical activates 14th hospital for adult AKI trial
- SeaStar Medical sees TAM for SCD in five clinical indications of $25B-$35B